These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36564070)

  • 1. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets.
    Jiang F; Shi Y; Wang Y; Ge C; Zhu J; Fang H; Zhang Y; Zhang Y; Jian H; Lei T; Lan S; Cao L; Yu H; Fang D
    Aging (Albany NY); 2023 Mar; 15(6):2066-2081. PubMed ID: 36920183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
    Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
    Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
    Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
    Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamic role of nucleoprotein SHCBP1 in the cancer cell cycle and its potential as a synergistic target for DNA-damaging agents in cancer therapy.
    Zhou M; Duan L; Chen J; Li Y; Yin Z; Song S; Cao Y; Luo P; Hu F; Yang G; Xu J; Liao T; Jin Y
    Cell Commun Signal; 2024 Feb; 22(1):131. PubMed ID: 38365687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
    Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
    Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
    Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
    Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Analysis of
    Du X; Xia W; Fan W; Shen X; Wu H; Zhang H
    Dis Markers; 2022; 2022():9365046. PubMed ID: 36118669
    [No Abstract]   [Full Text] [Related]  

  • 15. A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
    Chen R; Wu W; Chen SY; Liu ZZ; Wen ZP; Yu J; Zhang LB; Liu Z; Zhang J; Luo P; Zeng WJ; Cheng Q
    Front Immunol; 2022; 13():831542. PubMed ID: 35979347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Multiomics Analysis Identified IQGAP3 as a Potential Prognostic Marker in Pan-Cancer.
    Wang G; Zhou X; Li Y; Zhao M; Zou Y; Lu Q; Wu Y
    Dis Markers; 2022; 2022():4822964. PubMed ID: 36164370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
    Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological functions and therapeutic potential of SHCBP1 in human cancer.
    Lin Y; Cai H
    Biomed Pharmacother; 2023 Apr; 160():114362. PubMed ID: 36739763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.